S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
NASDAQ:IOVA

Iovance Biotherapeutics Stock Forecast, Price & News

$18.90
+0.12 (+0.64%)
(As of 12/8/2021 04:00 PM ET)
Add
Compare
Today's Range
$18.07
$19.21
50-Day Range
$16.55
$27.63
52-Week Range
$15.88
$54.21
Volume
1.21 million shs
Average Volume
2.21 million shs
Market Capitalization
$2.97 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.76
30 days | 90 days | 365 days | Advanced Chart
Receive IOVA News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.


Iovance Biotherapeutics logo

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Headlines

Iovance Biotherapeutics (NASDAQ:IOVA) Trading 13% Higher
December 7, 2021 |  americanbankingnews.com
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 2.8%
December 1, 2021 |  americanbankingnews.com
Iovance Biotherapeutics Becomes Oversold (IOVA)
November 12, 2021 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IOVA
Fax
N/A
Employees
241
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$4.45 per share

Profitability

Net Income
$-259.58 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
141,366,000
Market Cap
$2.97 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
12/09/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/24/2022

MarketRank

Overall MarketRank

1.68 out of 5 stars

Medical Sector

963rd out of 1,394 stocks

Biological Products, Except Diagnostic Industry

149th out of 202 stocks

Analyst Opinion: 3.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Iovance Biotherapeutics (NASDAQ:IOVA) Frequently Asked Questions

Is Iovance Biotherapeutics a buy right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Iovance Biotherapeutics stock.
View analyst ratings for Iovance Biotherapeutics
or view top-rated stocks.

How has Iovance Biotherapeutics' stock price been impacted by Coronavirus (COVID-19)?

Iovance Biotherapeutics' stock was trading at $29.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IOVA shares have decreased by 36.1% and is now trading at $18.90.
View which stocks have been most impacted by COVID-19
.

When is Iovance Biotherapeutics' next earnings date?

Iovance Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Iovance Biotherapeutics
.

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) announced its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($0.55) EPS for the quarter, missing the Zacks' consensus estimate of ($0.53) by $0.02. During the same quarter last year, the firm posted ($0.40) EPS.
View Iovance Biotherapeutics' earnings history
.

What price target have analysts set for IOVA?

12 equities research analysts have issued 12 month target prices for Iovance Biotherapeutics' shares. Their forecasts range from $20.00 to $51.00. On average, they anticipate Iovance Biotherapeutics' stock price to reach $38.20 in the next twelve months. This suggests a possible upside of 102.1% from the stock's current price.
View analysts' price targets for Iovance Biotherapeutics
or view top-rated stocks among Wall Street analysts.

Who are Iovance Biotherapeutics' key executives?

Iovance Biotherapeutics' management team includes the following people:
  • Frederick G. Vogt, President, CEO, Secretary & General Counsel
  • Igor P. Bilinsky, Chief Operating Officer
  • Jean-Marc Bellemin, CFO & Principal Accounting Officer
  • Friedrich Graf Finckenstein, Chief Medical Officer
  • Sara Pellegrino, VP-Investor Relations & Public Relations

What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (7.32%), Wellington Management Group LLP (5.67%), BlackRock Inc. (4.43%), Sumitomo Mitsui Trust Holdings Inc. (4.12%), Nikko Asset Management Americas Inc. (4.07%) and Franklin Resources Inc. (4.00%).
View institutional ownership trends for Iovance Biotherapeutics
.

Which major investors are selling Iovance Biotherapeutics stock?

IOVA stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Franklin Resources Inc., Goldman Sachs Group Inc., Frontier Capital Management Co. LLC, Candriam Luxembourg S.C.A., Jane Street Group LLC, and Artisan Partners Limited Partnership.
View insider buying and selling activity for Iovance Biotherapeutics
or view top insider-selling stocks.

Which major investors are buying Iovance Biotherapeutics stock?

IOVA stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Boxer Capital LLC, Perceptive Advisors LLC, Senator Investment Group LP, Commodore Capital LP, Two Sigma Investments LP, Cubist Systematic Strategies LLC, and BlackRock Inc..
View insider buying and selling activity for Iovance Biotherapeutics
or or view top insider-buying stocks.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Iovance Biotherapeutics' stock price today?

One share of IOVA stock can currently be purchased for approximately $18.90.

How much money does Iovance Biotherapeutics make?

Iovance Biotherapeutics has a market capitalization of $2.97 billion. The biotechnology company earns $-259.58 million in net income (profit) each year or ($2.06) on an earnings per share basis.

How many employees does Iovance Biotherapeutics have?

Iovance Biotherapeutics employs 241 workers across the globe.

What is Iovance Biotherapeutics' official website?

The official website for Iovance Biotherapeutics is www.iovance.com.

Where are Iovance Biotherapeutics' headquarters?

Iovance Biotherapeutics is headquartered at 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at (650) 260-7120 or via email at [email protected].


This page was last updated on 12/9/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.